CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

Labels of all GLP-1 receptor agonists now carry a warning about pulmonary aspiration during general anesthesia or deep ...

GLP-1 Receptor Agonist medications, such as Ozempic, combined with exercise and nutrition, can help reduce obesity, according ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

A new nationwide study led by investigators from Cedars-Sinai and other institutions reveals a significant rise in ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

The findings build on previous research that demonstrated GLP-1 receptor agonists, approved for the treatment of diabetes and obesity, could reduce alcohol intake in both animal studies and human ...

2024 / Informa Market's New Hope Network and Nutrition Business Journal (NBJ) unveil a special report highlighting how dietary supplements are complementary to the booming GLP-1 agonist drugs market.

The first GLP-1 receptor agonist approved for obesity was liraglutide ... These states include Hawaii (0.4%), Arizona (0.5%), ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally developed for managing type 2 diabetes—have rapidly increased in popularity.

2024 / Informa Market's New Hope Network and Nutrition Business Journal (NBJ) unveil a special report highlighting how dietary supplements are complementary to the booming GLP-1 agonist drugs market.